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Abstract 
Purpose: The purpose of this study is to examine the relationships among self-reported screening 
measures of ADHD, other psychiatric problems, and driving-related outcomes in a provincially  
representative sample of adults 18 years and older living in the province of Ontario, Canada. 
Methods: The study examined the results of the Centre for Addictions and Mental Health 
(CAMH) Ontario Monitor, an ongoing repeated cross-sectional telephone survey of Ontario 
adults over a two year period. Measures: ADHD measures (Adult ADHD Self-Report Scale-V1.1 
(ASRS-V1.1), previous ADHD diagnosis, ADHD medication use); psychiatric distress measures 
(General Health Questionnaire (GHQ12), pain, anxiety and depression medication use); 
antisocial behaviour measure (The Antisocial Personality Disorder Scale from the Mini-
International Neuropsychiatric Interview (APD)); substance use and abuse measures (alcohol, 
cannabis and cocaine), Alcohol Use Disorders Identification Test (AUDIT), Alcohol, Smoking 
and Substance Involvement Screening Test (ASSIST)); driving-related outcomes (driving after 
drinking, driving after cannabis use, street racing, collisions in past year) and socio-
demographics (gender, age, vehicle km travelled).  
Results: A total of 4014 Ontario residents were sampled, of which 3485 reported having a valid 
driver’s licence.  Overall, 3.22% screened positively for ADHD symptoms on the ASRS-V1.1 
screening tool. A greater percent of those who screened positively were younger, reported 
previous ADHD diagnosis and medication use, distress, antisocial behaviour, anti-anxiety and 
anti-depressant medication use, substance use and social problems compared to those who 
screened negatively. However, there were no statistically significant differences between those 
who screened positively or negatively for ADHD symptoms on self-reported driving after having 
two or more drinks in the previous hour, within an hour of using cannabis, marijuana or hash, in 
a street race or collision involvement as a driver in the past year. When a sequential regression 
was conducted to predict self-reported collisions, younger age, higher weekly kilometres driven 
showed higher odds of collision involvement, while the odds ratio for cannabis use ever, 
approached statistical significance. 
Discussion: This study is the first population-based study of a representative sample of adults 18 
years and older living in Ontario, Canada. These results showed no relationship between the 
ADHD screen and collision when age, sex and kilometres driven are controlled for. However, 
these analyses are based on self-report screeners and not psychiatric diagnoses and a limited 
sample of ADHD respondents. Thus, these results should be interpreted with caution. 
 
Introduction 
Attention Deficit Hyperactivity Disorder (ADHD) is a complex neurodevelopmental 
disorder. According to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, 
(DSM-5), ADHD includes symptoms of inattention, hyperactivity and impulsivity with clear 
evidence of impairment in multiple domains and onset of symptoms by age twelve (American 
Psychiatric Association 2013). Historically, ADHD was viewed as a diagnosis for children and 
adolescents as it was believed to diminish before adulthood (Goodman 2007).  However, follow-
up studies during the last 30 years have added ADHD to the range of adult psychiatric 
conditions, although evidence suggests that the number and severity of symptoms decline with 
age (Cuffe et al. 2005; Faraone et al. 2005). Diagnosis of ADHD is further complicated by the 
higher presence of comorbidities, such as mood, anxiety, conduct (CD), oppositional defiant 
(ODD), anti-social personality and substance use disorders in persons with diagnosed ADHD 
when compared to normal controls (Asherson et al. 2007; Kessler et al. 2006; Secnik et al. 2005; 
Weiss et al. 1985; Young et al. 2003). Indeed, Brassett-Harknett and Butler (2007) write: 
“Current expert opinion is that it is uncommon to find ‘pure’ AD/HD.” (p.195)   
Correlational and experimental studies have been conducted to assess whether 
adolescents and adults with ADHD have a higher propensity to risky driving, commit driving 
offences and be involved in collisions (Barkley et al. 1993, 2002; Fried et al. 2006; Murphy and 
Barkley, 1996; Nada-Raja et al. 1997; Woodward et al. 2000).  However, most studies exhibit 
serious methodological problems, such as referral bias, self-reporting, inappropriate or non-
defined comparison groups, non-blinded research staff, participant attrition, lack of adjustment 
for multiple comparisons, small sample sizes, lack of statistical controls for age, sex and driving 
exposure, and lack of controls for ADHD medication use and comorbidities.   
Observational studies conducted primarily with clinical samples have often shown higher 
rates of driving violations and collisions for persons with ADHD compared to control groups, 
with relative risks for collisions ranging from 0.42 to 18.3 (Vaa 2014). A recent meta-analysis 
found a relative collision risk for drivers with ADHD decreased significantly from 1.36 to 1.23 
when correcting for publication bias and controlling for driving exposure.  This risk could be 
even lower because ADHD drivers seem to drive more than controls, and the majority of studies 
in the meta-analysis lacked information on driving exposure (Vaa 2014). The relative collision 
risk was 1.86 in a sample of ADHD drivers in which the majority had comorbid conduct 
disorder, oppositional defiant disorder and/or other conduct problems, suggesting that these 
comorbidities may increase collision risk (Vaa 2014). The meta-analysis also clarified that 
although ADHD drivers had more speeding violations, they did not have more drinking-driving 
or reckless driving violations (Vaa 2014).  
The possibility that comorbid conditions in ADHD may account for negative driving 
outcomes is important for informing intervention and treatment choices. Some studies have 
found no relationships between an ADHD diagnosis and negative driving outcomes (Secnik et al. 
2005). Other studies have found that comorbid externalizing disorders, such as conduct, 
oppositional defiant or antisocial personality disorders, partially or fully explained negative 
driving-related outcomes (Barkley et al. 1993; Barkley and Cox 2007; Fried et al. 2006; 
Thompson et al. 2007; Woodward et al. 2000). In an early, well-cited study of ADHD and 
negative driving outcomes, Barkley et al. (1993) wrote: “All of the negative driving-related 
outcomes as well as driving skill deficiencies are significantly related to the degree of antisocial 
symptoms (ODD/CD) shown by these subjects. The degree of ADHD symptoms seems to make 
an additional unique contribution only to the number of times a subject had illegally driven 
without a driver’s license”. (p. 217)  However, the authors then concluded: “An almost fourfold 
increase in the average frequency of being involved in motor vehicle crashes as drivers was 
noted for subjects with ADHD relative to control subjects” (Barkley et al. 1993. pp.217-218). 
Yet other studies found no effects of comorbidities on the positive relationship between ADHD 
and negative driving outcomes. Barkley et al. (2002) found a relationship between ADHD and 
traffic citations, collisions and licence suspensions, but failed to replicate the associations they 
previously found between oppositional defiant disorder and driving-related outcomes.  
 Internalizing disorders are also commonly comorbid with ADHD in adolescents and 
adults (Biederman et al. 2006; Fayyad et al. 2007; Secnik et al. 2005). Internalizing disorders 
have been associated with negative driving outcomes including increased collision and injury 
risk in general population samples (Mann et al. 2010; Vingilis and Wilk 2008). However, limited 
research is available on internalizing disorders, ADHD and negative driving outcomes and show 
contradictory findings (Barkley et al. 2002; Fried et al. 2006).  
 Studies of adults with ADHD have also found higher rates of alcohol and drug use and 
problems when compared with control samples (Brassett-Harknett and Butler 2007; Goodman 
2007;  Kessler et al. 2006; Secnik et al. 2005; Wolraich et al. 2005; Young et al. 2003). 
However, the limited studies that examined drinking driving behaviours of ADHD adults have 
found mixed results.  Studies have found that clinical ADHD and community control groups did 
not differ in the proportion that self-reported drinking driving or drinking driving collisions 
(Barkley et al. 1993, 1996; 2002; Thompson et al. 2007), although those with conduct problems 
did report more impaired driving (Thompson et al. 2007). Yet longitudinal studies found that 
those with attentional difficulties or ADHD were significantly more likely to report driving after 
drinking, driving while seriously intoxicated, and to be arrested for drinking driving (Nada-Raja 
et al. 1997; Woodward et al. 2000). However, no studies have examined cannabis or cocaine use 
and driving in relation to ADHD. 
Research has generally found evidence of improved driving among adolescent and adult 
drivers with ADHD medication use (Cox et al. 2000, 2006; Hechtman et al. 1984; Sobanski et al. 
2008; Wolraich et al. 2005). One follow-up study of adults who had been diagnosed with ADHD 
as children found that those who had received medication in childhood for their ADHD reported 
fewer collisions as adults compared to those who went untreated or to non-ADHD controls.  
However, self-reports of the cost of the collisions, extent of bodily injury and use of alcohol, 
drugs or emotional states at time of the collision did not differ among groups (Hechtman et al. 
1984). Some experimental, laboratory simulator studies have found better simulator driving 
performance in persons using ADHD medications compared to placebo control groups (Cox et 
al. 2000, 2004, 2006). However, other research has shown poor concordance between laboratory- 
or clinic-based measures of response to ADHD medication and actual performance (Thompson 
et al. 2007). A simulator study found differences in only 3 of 18 measures between the ADHD 
placebo condition and the low or high doses of methylphenidate conditions (Barkley et al. 2005).  
Nevertheless, the authors conclude: “the results, when placed in the context of prior studies of 
stimulants on driving performance, continue to recommend their clinical use as one means of 
reducing the driving risks in ADHD teens and adults” (Barkley et al. 2005, p. 121).  
One important methodological challenge is the use of clinical samples. Clinical samples 
are derived through a series of filters which introduce a series of biases. ADHD samples are 
generally drawn from various treatment facilities. However, only a small proportion of those 
with ADHD symptoms are diagnosed and/or seek treatment through clinics and hospital units 
(Cuffe et al. 2005). For example, prevalence differences for ADHD in boys and girls vary by 
sampling methods, with clinically-referred studies having gender differences close to 9:1, while 
epidemiological studies have gender differences closer to 3:1 (Gerson 2002). Some suggest that 
girls with ADHD display less disruptive behaviours, which lead to fewer referrals than the 
attention-getting conduct of boys (Chen and Taylor 2005; Gerson 2002). Clinical samples have 
the advantage of extensive assessment but the disadvantage of a lack of representativeness of 
those with ADHD symptoms (Cunningham and Boyle 2002; Rowland et al. 2002). Clinical 
samples also seem to show more symptoms, impairment, comorbidities and other differences 
compared to community samples (Rowland et al. 2002). For example, Young et al. (2003) found 
fewer life history, social functioning and comorbidity differences between an ADHD clinical 
group drawn from an adult ADHD assessment clinic that met the diagnostic criteria for ADHD 
and a clinical control group that did not meet ADHD criteria, than between the ADHD group and 
a non-clinical control group. Population-based samples can be used for making inferences to the 
general population (Cunningham and Boyle, 2002; Rowland et al. 2002). Thus, a population-
based study can contribute to our understanding of ADHD, risky driving and covariates, 
although it is important to point out that large, population-based surveys must rely on screening 
instruments and thus are limited by the measurements. 
 The purpose of this study is to examine the relationships among self-reported screening 
measures of ADHD, other psychiatric problems, and driving-related outcomes in a provincially 
representative sample of adults living in the province of Ontario, Canada.  
Methodology 
The data are based on telephone interviews with 4,014 respondents over 24 months between 
January, 2011 and December 2012. These data were collected through the Centre for Addiction 
and Mental Health (CAMH) Monitor, an ongoing cross-sectional, computer assisted telephone 
survey (landlines and cell phones) of Ontario adults (ages 18 or older) using a stratified two-
stage probability selection procedure occurring each quarter.  The survey is conducted by CAMH 
and administered by the Institute for Social Research at York University (see Ialomiteanu and 
Adlaf 2012 for details). Each monthly cycle uses a two-stage probability sampling procedure. In 
the first stage, a random sample of telephone numbers was selected with equal probability from 
within each regional stratum. In the second stage, one respondent aged 18 or older who was able 
to complete the interview in English was then selected from within each household according to 
the most recent birthday of all household members. Response rates based on estimated eligible 
sample averaged 52.89%. The study received ethical approval from the CAMH, York University 
and the University of Western Ontario research ethics boards. 
Measures 
ADHD measures  
 The Adult ADHD Self-Report Scale-V1.1 (ASRS-V1.1) was developed by Kessler et al. 
(2005) in conjunction with revision of the WHO Composite Diagnostic Interview.  The 
screener consists of 6-items, each with 5-point Likert scale response options, found to be 
most predictive of a DSM IV-based diagnosis of ADHD (Able et al. 2007; Adler et al. 
2006; Kessler et al. 2005, 2007).  A positive ADHD symptoms screen is a total score 
greater than 13 (Kessler et al. 2007).   
 Previous ADHD diagnosis was assessed by the item ‘have you ever been diagnosed with 
Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD) 
by a doctor or health care professional?’ Youth endorsing an ADHD diagnosis also 
concurrently reported significantly more DSM-IV symptoms of ADHD than youth not 
endorsing a diagnosis of ADHD (Langhinrichsen-Rohling et al. 2005).  
 ADHD Medication use was assessed by items querying participants if and when they had 
ever been treated with medication for ADHD or ADD by a doctor or health care 
professional?’ (adapted from Ontario Student Drug Use and Health Survey, Paglia-Boak 
et al. 2012). 
Psychiatric distress (anxiety/depression) measures and medication use 
 The General Health Questionnaire (GHQ12) is a widely used 12-item screening 
instrument, with good psychometric properties, for current psychiatric distress. It 
captures depression/anxiety and problems with social functioning (Donath 2001; 
Goldberg and Hillier 1979; Hardy et al. 1999). A score of three and higher is a positive 
screen;  
 Pain/anxiety/depression medication use: In the past 12 months have you taken any 
prescription medication: for pain? to reduce anxiety or panic attacks? to reduce 
depression? 
Antisocial behaviour measure:  
 Antisocial Personality Disorder Scale from the Mini-International Neuropsychiatric 
Interview (MINI-APD), a 12-item, dichotomous scale, was designed to provide a short 
clinical screening tool to assess whether the following sets of delinquencies (truancy, 
cheating/lying/stealing, bullying, hurting animals/people) were committed before age 15  
and after age 15 (Sheehan et al., 1998). We excluded one item of the MINI-APD (forced 
someone to have sex before age 15), as required by the ethics review board. A score of 
three or more on the latter six MINI-APD questions indicated a positive APD screen.  
Substance use and abuse measures:  
 Lifetime cannabis and cocaine use;  
 Binge drinking ( five or more drinks at the same sitting or occasion at least once in the 
past 12 months);  
 Alcohol Use Disorders Identification Test (AUDIT) is a 10-item, validated screening 
instrument developed by the WHO, to detect individuals at the less severe end of the 
spectrum of alcohol problems, with a score eight and greater indicating hazardous alcohol 
use (Newcombe et al. 2005; Saunders et al. 1993; WHO ASSIST Working Group 2002). 
 The cannabis subscale of the Alcohol, Smoking and Substance Involvement Screening 
Test (ASSIST) is a 6-item screening instrument to assess, for users of cannabis, the risk 
of experiencing health and other problems (e.g., social, financial, legal, relationship) from 
their current pattern of use, with score four and greater indicating moderate or high risk 
of problems (WHO ASSIST Working Group, 2002).  
Driving-related problem behaviours:  
 Drinking/driving: (“…have you driven a motor vehicle after having two or more drinks in 
the previous hour?”); cannabis use/driving: (“…have you driven a motor vehicle within 
an hour of using cannabis, marijuana or hash?”; street racing: (…”how many times, if at 
all, have you driven a car, truck or SUV in a street race?”) and collision involvement: 
(“how often, if at all, were you involved in an accident or collision involving any kind of 
damage to you or another person or vehicle while you were driving…”, were each 
assessed according to whether or not respondents reported one or more instances “during 
the past 12 months”.  
Socio-demographics:  
 Sex (male = 0, female= 1); age; kilometres driven per week. 
Statistical Analysis 
IBM SPSS Statistics 20 (IBM SPSS Statistics, 2011) software was used in all analyses. The 
results in this paper are based on “valid” responses (n's) such that missing data (i.e. “don’t know” 
responses and refusals) were excluded from analyses. The percentages reported are based on the 
weighted sample size and are considered representative for the population surveyed (Ialomiteanu 
and Adlaf, 2004). Bivariate analyses (X2s and t-tests) were used to compare differences between 
respondents who screened positively and negatively for ADHD symptoms and for those who 
reported at least one collision versus none in the past year. The results are interpreted using a 
Bonferroni correction of .0028 for 18 comparisons. A sequential logistic regression was 
performed considering self-reported collisions as the dependent variable. Age (18-24, 25-44,45-
64,≥65), sex and driving exposure as control variables were entered in the first block, ADHD 
screening status in the second block, antisocial behaviour screener and distress in the third block 
and substance use/abuse variables of the ASSIST, cannabis and cocaine use in the fourth block. 
Sequential logistic regression is a commonly used procedure that allows the researcher to assign 
order of entry of variables based on logical or theoretical considerations and to determine 
whether prediction of the dependent variable improves with the additional independent variables 
added to the equation (Tabachnik and Fidell, 2007).  The ordering of variables for the sequential 
logistic regression reflected the conceptualization and findings of the ADHD and comorbidity 
literature with ADHD, as a neurodevelopmental disorder occurring prior to psychiatric distress 
and antisocial behaviours, which could affect substance use and abuse (Acherson et al. 2007; 
Goodman 2007; Hechtman et al. 1984; Secnik et al. 2005; Weiss et al. 1985; Wolraich et al. 
2005; Young et al. 2003).  
Results 
Overall, 3.22% of the sample of self-reported licensed drivers screened above the cut-off for 
positive ADHD symptoms. Table 1 shows significant differences between those who screened 
positively and negatively for ADHD symptoms. A greater percent of those who screened 
positively were younger, reported previous ADHD diagnosis and medication use, distress, 
antisocial behaviour, anti-anxiety and anti-depressant medication use, substance use and social 
problems compared to those who screened negatively. However, there were no statistically 
significant differences between those who screened positively or negatively for ADHD 
symptoms on self-reported drinking driving cannabis use and driving or in a street race. Also no 
between group differences were found for collision involvement as a driver in the past year. 
 Few significant differences were found for respondents who reported a collision in the 
last 12 months compared to those who reported no collisions (Table 2). Only age, lifetime 
cannabis use, the ASSIST, and racing were significantly associated with self-reported collision 
involvement in the past year.  
 Table 3 provides the results of the sequential logistic regression. In block 1 the control 
variables of age, sex and driving exposure provided statistically significant improvement over 
the constant only model (X2=26.458, df=5, p<.000). The odds ratio for age over 65 showed 
statistical significance, indicating a lower odds of respondents over 65 years of age reporting at 
least one collision compared to the 16-24 year old group (OR=.382, CI .185, .789). The odds 
ratio for driving exposure was also statistically significant (OR=1.000, CI 1.000, 1.001). In block 
2, the entry of ADHD screener status did not statistically significantly improve the model (block 
X2=.130, df=1, p=.718) over and above that accounted for by the control variables. When 
antisocial behaviour and the distress measures were added in block 3, the model showed no 
improvement (block X2=2.097, df=2, p=.350). In block 4, the entry of the substance use and 
problems measures (ASSIST, use of cannabis in lifetime and use of cocaine in lifetime) showed 
a statistically significant model improvement (block X2=9.521, df=3, p=.023). Although no 
individual variables showed statistically significant odds ratios, use of cannabis ever neared 
statistical significance (OR=1.404, CI .992, 1.988, p=.056). The final model correctly classified 
99.1% of no collision status, 2.2% of collision status and 93.5% of all cases overall at a cut-off 
value of .150. 
Discussion 
This study is the first Canadian population-based assessment of ADHD symptoms and driving 
outcomes. Our ADHD symptom prevalence of 3.1% is congruent with the average ADHD 
prevalence of 3.4% found in a review of international studies of ADHD prevalence using similar 
sampling methodology (Fayyad et al. 2007). Consistent with other studies, the results show that a 
greater percentage of those who screened positively for ADHD symptoms compared to those 
who screened negatively for ADHD symptoms reported higher rates of psychiatric problems 
(distress, antisocial behaviours and substance use and problems).  Additionally, a greater 
percentage of those who screened positively for ADHD symptoms compared to those who 
screened negatively for ADHD symptoms reported taking anti-anxiety and anti-depressant 
medications in the past year. However, no statistically significant differences were found 
between those who screened positively and negatively for ADHD symptoms and self-reported 
driving behaviours and outcomes, namely driving after having two or more drinks in the 
previous hour, within an hour of using cannabis, marijuana or hash, in a street race or collision 
involvement as driver in past year. 
 Examination of collision status identified cannabis use and problems and racing as 
variables associated with collisions but not ADHD positive symptoms, ADHD diagnosis or 
ADHD medication use, although the small cell sizes prevent definitive statements regarding this 
lack of positive results. A significantly greater percentage of persons who reported ever using 
cannabis and who scored in the moderate/high problems for cannabis use reported a collision in 
the past year. Studies on the relationship between cannabis use and negative driving outcomes 
have generally shown a positive relationship, particularly for acute cannabis consumption, 
although a number of studies and reviews have also found no relationship (Asbridge et al. 2012; 
Elvik 2013; Li et al. 2012; Mann et al. 2007; Ramaekers et al. 2004; Vingilis and Macdonald 
2002). In the current study, no relationship was found between self-reported driving within an 
hour of using cannabis and collisions, suggesting that the relationship found between ever used 
cannabis, the ASSIST and collisions may be due to factors other than driving impairment. The 
sequential logistic regression indicated that when age and driving exposure were controlled, 
cannabis use was no longer associated with higher odds of self-reported collisions, although the 
association did approach statistical significance.   
 These data provide a valuable perspective on the relationship between ADHD symptoms 
and collision involvement in a large, population-based sample.  Previous studies have indicated 
that individuals with ADHD are at substantially greater risk of collision involvement (e.g., 
Barkley et al. 1993).  However, these studies were typically based on clinical samples that may 
be subject to substantial forms of bias, as well as failing to control for comorbidities and 
important confounders such as driving exposure.  Other studies found the relationship between 
ADHD status and negative driving outcomes mediated by other comorbidities (Barkley et al. 
1993; Barkley and Cox 2007; Fried et al. 2006; Thompson et al. 2007; Woodward et al. 2000) 
and yet other studies found no relationship between ADHD status and negative driving outcomes 
(Secnik et al. 2005).  A recent meta-analysis suggested that evidence for an association of 
ADHD with driving risks decreased as potential confounders were controlled (Vaa 2014).  In our 
study, we were able to control for demographic and driving exposure measures and 
comorbidities including psychiatric distress and substance use and problems.  When we did so, 
we found no evidence for a significant association of ADHD symptoms with collision risk in this 
sample.   
 Our results are thus in substantial agreement with the results of the recent meta-analysis 
by Vaa (2014) in suggesting that the strong association of ADHD with collision risk seen in 
some earlier studies may have been an artefact of the study designs used and a failure to control 
for potential confounders.   Studies of clinical samples are subject to referral bias, and among 
individuals with ADHD other comorbid conditions, many of which are also associated with 
increased collision risk, are often observed, as shown in Table 1.  Thus, findings in previous 
studies suggesting that ADHD is associated with substantively increased collision risk may have 
instead been reflecting the impact of design bias and comorbid factors.   
 This does not mean that there is no need to be concerned about collision risk among those 
experiencing ADHD.  Instead, it suggests the need for more complex broad-based research as 
ADHD is a complex disorder with heterogeneity in neuropsychological pathways, comorbidities 
and symptom presentations (Coghill et al. 2005; Nigg et al. 2005; Toplak et al. 2008; Wåhlstedt 
et al. 2009). Driving and collision risk research among those with ADHD also needs to include 
road safety researchers so that collision risk may better be assessed by including validated 
methods and measures and other factors known to increase risk, such as drug use.  
 The results of this study are subject to important limitations.  These data are based on 
self-report screeners and do not reflect the breadth of information needed for clinical diagnoses. 
This is a key issue because the current study only reflects self-reported symptoms and does not 
examine impaired functioning and other issues related to specific diagnoses. Thus, this 
population based sample may represent functioning persons with some ADHD and/or other 
comorbid symptoms but not actual diagnoses and as such, the study findings may be biased 
toward persons with fewer negative driving outcomes. It is not possible to assess sampling bias 
as no information on non-respondents was available. Thus it is unknown whether those with 
ADHD were more or less likely to participate in the survey, although the age trends and 
relationships found in Table 1 between ADHD symptoms and more comorbidities and other 
difficulties, are consistent with many other studies (e.g. Able et al.2007; Brassett-Harknett and 
Butler 2007; Cuffe et al. 2005; Faraone et al. 2005) and serve to validate the ADHD self-report 
construct in a community sample.  
 Other variables, such as collisions, drinking driving, etc. are also based on self-reports 
and can be subject to memory problems and social desirability, although in our study 6.1% 
reported a collision while official statistics indicate about 4% of licensed drivers yearly are 
reported to police to be involved in a collision in Ontario (Ministry of Transport of Ontario, 
2014), suggesting that underreporting among survey respondents did not occur. Other Canadian 
research examining whether self-reported collision injury rates in a national population survey 
using equivalent sampling methods to our survey were a valid measure of police-reported, 
official collision injury rates in Canada, found no significant differences in rates when the two 
datasets were compared for the gender and age categories or for trends over time (Roberts et al. 
2008), indicating that that self-reports for collisions may be reasonably accurate.  Additionally, 
although the response rate over 50% is good for a telephone survey and data were weighted, the 
sample could potentially be biased.   Finally, although the total sample size is over 4000, cell 
sizes can be very small because psychiatric problems, such as ADHD, substance use and 
collisions have low prevalence; small cell sizes and large CIs suggest a low level of precision, as 
indicated in some of the variables in Table 3. 
 Despite these limitations, these observations are of substantial interest.  Additional 
research to confirm that the impact of ADHD symptoms on collision risk is more modest or more 
complex than suggested in previous studies is needed to ensure an appropriate response to 
potential traffic safety concerns associated with this condition.   
 
 
Acknowledgements  
 
This study was supported by a Canadian Institutes for Health Research operating grant (#MOP 
102537).  
References 
Able SL, Johnston JA, Adler LA, Swindle RW. Functional and psychosocial impairment in 
adults with undiagnosed ADHD. Psychol Med. 2007;37:97-107. 
 
Adler LA, Spencer T, Faraone SV, et al. Validity of pilot adult ADHD self-report scale (ASRS) 
to rate adult ADHD symptoms. Ann Clin Psychol. 2006;18(3):145-8. 
 
American Psychiatric Association. Desk Reference to the Diagnostic Criteria from DSM-5. 
Arlington, VA: American Psychiatric Association; 2013. 
 
Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle 
collision risk: systematic review of observational studies and meta-analysis. Br Med J. 
2012;344:e536-545. 
 
Asherson P, Chen W, Craddock B, Taylor E. Adult attention-deficit hyperactivity disorder: 
recognition and treatment in general adult psychiatry. Br J Psychiat. 2007;190:4-5. 
 
Barkley RA, Cox D. A review of driving risks and impairment associated with attention-
deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J 
Safety Res. 2007;38:113–128.  
 
Barkley RA, Guevremont DC, Anastopoulos AD, DuPaul GJ, Shelton TL. Driving-related risks 
and outcomes of attention deficit hyperactivity disorders in adolescents and young adults: a 3 to 
5 year follow-up survey. Pediatrics. 1993;92:212–218.  
 
Barkley RA, Murphy KR Kwasnik D. Motor vehicle driving competencies and risks in teens and 
young adults with attention deficit hyperactivity disorder. Pediatrics. 1996;98:1089-1095. 
 
Barkley RA, Murphy KR, DuPaul GJ, Bush T. Driving in young adults with attention deficit 
hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive 
functioning. J Int Neuropsychol Soc. 2002;8:655–672. 
 
Barkley RA, Murphy KR, O’Connell T, Connor D. Effects of two doses of methylphenidate on 
simulator driving performance in adults with attention deficit hyperactivity disorder. J Safety 
Res. 2005;36:121–131. 
 
Barkley RA, Murphy KR, O’Connell T, Anderson D, Connor DF. Effects of two doses of 
alcohol on simulator driving performance in adults with attention-deficit/hyperactivity disorder. 
Neuropsychol. 2006;20:77–87. 
 
Biederman J, Faraone SV, Monuteaux MC, et al. Gender effects of attention deficit hyperactivity 
disoerder in adults, revisited. Biolog Psychiatry. 2004:55;692-700. 
 
Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit 
hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006;36:167-79. 
 
Brassett-Harknett A,  Butler N. Attention-deficit/hyperactivity disorder: An overview of the 
etiology and a review of the literature relating to the correlates and lifecourse outcomes for men 
and women. Clin Psychol Rev.  2007;27:188-210.  
 
Chen W, Taylor E. Resilience and self-control impairment. In: Goldstein S, Brooks RB, Eds. 
Handbook of Resilience in Children 7th ed. New York: Springer;2005;257-278. 
 
Coghill D, Nigg J, Rothenberger A, Sonuga-Barke E, Tannock R. Whither causal models in the 
neuroscience of ADHD? Devel Sci. 2005;8:105-114. 
 
Cox D, Merkel R, Kovatchev B, Seward R. Effect of stimulant medication on driving 
performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-
blind placebo controlled trial. J Nerv Ment Dis 2000;188:230–234. 
 
Cox D, Merkel R, Moore M, Thorndike F, Muller C, Kovatchev B. Relative benefits of stimulant 
therapy with OROS methylphenidate versus mixed amphetamine salts extended release in 
improving the driving performance of adolescent drivers with attention-deficit/hyperactivity 
disorder. Pediatrics 2006;118:E704–E710. 
 
Cuffe SP, Moore CG, McKeown RE. Prevalence and correlated of ADHD symptoms in the 
National Health Interview Survey. J Atten Disord. 2005;9:392-401. 
 
Cunningham CE, Boyle MH. Preschoolers at risk for attention-deficit hyperactivity disorder and 
oppositional defiant disorder: family, parenting, and behavioral correlates. J Abnorm Child 
Psychol. 2002;30:555-69. 
 
Donath S. The validity of the 12-item General Health Questionnaire in Australia: a comparison 
between three scoring methods. Austral N Z J Psych 2001;35:231-5. 
  
Elvik R. Risk of raod accident associated with the use of drugs: A systematic review and meta-
analysis of evidence from epidemiological studies. Acc Anal Prev. 2013;60:254-267. 
 
Faraone SV, Biederman J, Mick E. The age dependent decline of attention deficit hyperactivity 
disorder: a meta-analysis of follow-up studies. Psychol Med. 2005;35:1-7. 
 
Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult 
attention-deficit hyperactivity disorder. Brit J Psychiatry 2007;190:402-9. 
 
Fischer M, Barkley RA, Smallish L, Fletcher K. Hyperactive children as young adults: driving 
abilities, safe driving behavior, and adverse driving out-comes. Accid Anal Prev. 2007;39:94–
105. 
 
Fried R, Petty C, Surman C, Reimer B, et al. Characterizing impaired driving in adults with 
attention deficit/hyperactivity disorder: a controlled study. J Clin Psychiat. 2006;67:567–574. 
 
Gershon J. A meta-analytic review of gender differences in ADHD. J Atten Disord. 
2002;5(3):143-54.  
 
Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med. 
1979;9:139-45. 
 
Goodman DW, The consequences of Attention-Deficit/Hyeractivity Disorder in adults. J 
Psychiat Practice. 2007;13:318-327. 
 
Hardy GE, Shapiro DA, Haynes CE, Rick JE. Validation of the General Health Questionnaire-12 
using a sample of employees from England's health care services. Psychol Assess. 1999;11:159-
65. 
 
Hechtman L, Weiss G, Perlman T. Young adult outcome of hyperactive children who received 
long-term stimulant treatment. J Am Acad Child Adolesc Psychiatry. 1984;23:261-269. 
 
Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report 
Scale (ASRS): a short screening scale for use in the general population. Psychol Med 
2005;35:245-56. 
 
Kessler RC, Adler L, Barkley RA, et al. The prevalence and correlates of adult ADHD in the 
United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 
163:716–723. 
 
Kessler RC, Adler LA, Gruber MJ, Sarawate CA, Spender T, Van Brunt DL. Validity of the 
World Health Organization Adult ADHD Self-Report Scale (ASRS). Screener in a representative 
sample of health plan members. Int J Methods Psychol Res 2007;16(2):52-65. 
 
Ialomiteanu A, Adlaf EM.  CAMH Monitor 2011: metadata user’s guide. Toronto, ON: Centre 
for Addiction and Mental Health; 2012. [cited 2014 Feb 25] Available from: 
http://www.camh.net/Research/camh_monitor.html 
 
Langhinrichsen-Rohli J, Rebholz C, O-Brien N, O'Farrill-Swails L, Ford W. Self-reported co 
morbidity of depression, ADHD, and alcohol/substance use disorders in male youth offender 
residing in an alternative sentencing program. J Evidence-based Social Work. 2005;2:1-17. 
 
Li MC, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G. Marijuana use and motor vehicle 
crashes. Epi Rev. 2012;34:65-72. 
 
Mann RE, Adlaf E, Zhao J, et al. Cannabis use and self-reported collisions in a representative 
sample of adult drivers. J Safety Res. 2007;38:669-674. 
 
Mann RE, Asbridge M, Stoduto G, et al. Psychological distress and collision involvement among 
adult drivers.  Stress Health. 2010;26:127-134.  
 
 
Ministry of Transportation of Ontario. Ontario Road Safety Annual Report 2010. 
http://www.mto.gov.on.ca/english/safety/orsar/orsar10/ORSAR10.pdf 
 
Nada-Raja S, Langley JD, McGee R, Williams SM, Begg DJ, Reeder AI. Inattentive and 
hyperactive behaviors and driving offenses in adolescence. J Am Acad Child Adolesc Psychiatry. 
1997;36:515-522. 
 
Newcombe DAL, Humeniuk RE, Ali R. Validation of the World Health Organization Alcohol, 
Smoking and Substance Involvement Screening Test (ASSIST): report of results from the 
Australian site. Drug Alcohol Rev. 2005;24(3):217-26. 
 
Nigg Jt, Willcutt EG, Doyle AE, Sonuga-Barke EJS. Causal heterogeneity in attention-
deficit/hyperactivity disorder: Do we need neuropsychologically impaired substypes? Biol 
Psychiatry. 2005;57:1224-1230. 
 
Paglia-Boak A, Mann RE, Adlaf EM, Hamilton HA, Beitchman JH, Wolfe D, et al. Detailed 
OSDUHS findings. The mental health and well-being of Ontario students 1991-2011. (CAMH 
Research Document Series No. 33). Toronto, ON: Centre for Addiction and Mental Health; 
2012. 
 
Reimer B, D’Ambrosio LA, Coughlin JE, Fried R, Biederman J. Task-induced fatigue and 
collisions in adult drivers with attention deficit hyper-activity disorder. Traffic Inj Prev. 
2007;8:290–299. 
 
Reimer B, Mehler B, D’Ambrosio LA, Fried R. The impact of distractions on young adults 
drivers with attention deficit hyperactivity disorder (ADHD). Accid Anal Prev. 2010;42:842–851 
 
Roberts SE, Vingilis E, Wilk P, Seeley J. A comparison of self-reported motor vehicle collision 
injuries compared with official collision data: An analysis of age and sex trends using the 
Canadian National Population Health Survey and Transport Canada data. Accid Anal Prev. 
2008;40:559-566. 
 
Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity 
disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8:162-70. 
 
Saunders JB, Asland OG, Babor TF, De La Fuente JR, Grant M. Development of the Alcohol 
Use Disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of 
persons with harmful alcohol consumption--II. Addiction. 1993;88(6):791-804. 
 
Secnik K, Swensen A, Lage MJ. Comorbidities and costs of adult patients diagnosed with 
attention-deficit hyperactivity disorder.  Pharmacoecon. 2005;23:93-102. 
 
Sheehan DV, Lecrubier Y, Shehhan KH, et al. The Mini-International Interview (M.I.N.I.): the 
development and validation of a structured diagnostic interview for DSM-IV and ICD-10. J Clin 
Psychiatry 1998;59 Suppl 20:22-33. 
 
Smart RG, Mann RE. Is road rage a serious traffic problem? Traffic Inj Prev. 2002;3:183–189. 
 
Sobanski E, Sabljic D, Alm B, et al. Driving-related risks and impact of methylphenidate 
treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD). J Neural 
Transm. 2008;115:347–356 
 
Thompson AL, Molina BS, Pelham Jr W, Gnagy EM. Risky driving in adolescents and young 
adults with childhood ADHD. J Pediatric Psychol. 2007;32:745–759. 
 
Toplak ME, Connors L, Shuster J, Knezevic B, Parks S. Review of cognitive, cognitive-
behavioral and neural-based interventions for Attention-Deficit/Hyperactivity Disorder (ADHD). 
Clin Psychol Rev. 2008;28:801-823. 
 
Vaa T. ADHD and relative risk of accidents in road traffic: A meta-analysis. Accid Anal Prev. 
2014;62:414-425. 
 
Vingilis E, Macdonald S. Review: drugs and traffic collisions. Traffic Inj Prev.2002;3:1-11. 
 
Vingilis E, Wilk P. The effects of health status, distress, alcohol and medicinal drug use on 
subsequent motor vehicle injuries. Accid Anal Prev. 2008;40:1901-1907. 
 
Wåhlstedt C, Thorell LB, Bohlin G. Heterogeneity in ADHD: Neuropsychological pathways, 
comorbidity and symptom domains. J Abnorm Child Psychol. 2009;37:551-564. 
 
Weafer J, Camarillo D, Fillmore MT, Milich R, Marczinski CA. Simulated driving performance 
of adults with ADHD: comparisons with alcohol intoxication. Exper Clin Psychopharmacol. 
2008;16:251–263. 
 
Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: A 
controlled prospective 15- year follow-up of 63 hyperactive children. J Am Acad Child Psychiat. 
1985;24:211-220. 
 
Wells-Parker E, Ceminsky J, Hallberg V, et al. An exploratory study of the relationship between 
road rage and crash experience in a representative sample of US drivers. Accid Anal Prev. 34, 
271–278. 
 
WHO ASSIST Working Group. Alcohol, smoking and substance involvement screening test 
(ASSIST): Development, reliability and feasibility. Addiction 2002;97:1183-94.  
 
Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/hyperactivity disorder among 
adolescents: A review of the diagnosis, treatment, and clinical implications.  Pediatrics. 
2005;115:1734–1746 
 
Woodword L, Fergusson DM, Horwood LJ. Driving outcomes of young people with attentional 
difficulties in adolescence. J Am Acad Child Adolesc Psychiatry. 2000;39:627434. 
 
Young S, Roone B, Tyson C. Comorbidity and psychosocial profile of adults with Attention 
Deficit Hyperactivity Disorder. Pers Indiv Differ. 2003;35:743-755.
Table 1 ADHD screener status by socio-demographic, previous ADHD diagnosis and 
medication use, comorbidities, substance use/abuse and driving variables. 
Variables  ADHD+ screen ADHD- screen 
  N % N % P*value 
age 18-24 
25-44 
45-64 
≥65 
21
45
36
3
20.0
42.9
34.3
2.9
346 
1133 
1193 
524 
10.8 
35.5 
37.3 
16.4 
.000* 
sex Female 
male 
57
48
54.3
45.7
1650 
1606 
50.7 
49.3 
.466 
ADHD 
diagnosis 
Previous diagnosis 
never 
11
93
10.6
89.4
60 
3194 
1.8 
98.2 
.000* 
ADHD meds Taken 
Never taken 
10
94
9.6
90.4
40 
3214 
1.2 
98.8 
.000* 
Distress (GHQ) Yes (≥3) 
No (0-2) 
49
56
46.7
53.3
402 
2854 
12.3 
87.7 
.000* 
ASP screen Yes (≥3) 
No (0-2) 
4
94
4.1
95.9
7 
3157 
0.2 
99.8 
.000* 
Anti-anxiety 
meds 
Taken last 12 mo 
No 
37
67
35.6
64.4
218 
3034 
6.7 
93.3 
.000* 
Anti-depressant 
meds 
Taken last 12 mo 
No 
35
70
33.3
66.7
183 
3067 
5.6 
94.4 
.000* 
Anti-pain meds Taken last 12 mo 
No 
31
73
29.8
70.2
651 
2580 
20.1 
79.9 
.016 
Binge drinking 
5+ 
Yes (≥1past yr) 
No  
58
47
55.3
44.8
1348 
1884 
41.7 
58.3 
.006 
Cannabis use 
lifetime 
Yes (ever in lifetime) 
No (never) 
77
28
73.3
26.7
1338 
1907 
41.2 
58.8 
.000* 
Cocaine use 
lifetime 
Yes (ever in lifetime) 
No (never) 
23
82
21.9
78.1
213 
3040 
6.5 
93.5 
.000* 
AUDIT Yes (≥8) 
No (0-7) 
23
80
22.3
77.7
419 
2763 
13.2 
86.8 
.007 
ASSIST Moderate/high (≥4) 
Low (0-3) 
13
91
12.5
87.5
142 
3108 
4.4 
95.6 
.000* 
Drinking 
driving 
Past yr 
No 
3
102
2.9
97.1
187 
3070 
5.7 
94.3 
.208 
Cannabis 
driving 
Past yr 
No 
4
101
3.8
96.2
61 
3176 
1.9 
98.1 
.160 
Racing Past yr 
No 
2
103
1.9
98.1
28 
3223 
0.9 
99.1 
.264 
Collisions Past yr 
No 
13
92
12.4
87.6
183 
3073 
5.6 
94.4 
.004 
*Significant P value with Bonferroni adjustment for 18 comparisons = .0028  
Table 2 Collision status by ADHD screener status, previous ADHD diagnosis and 
medication use, comorbidities, substance use/abuse and driving variables. 
Variables  Collision past yr No collision past yr 
  N % N % P*value 
age 18-24 
25-44 
45-64 
≥65 
34
91
66
17
16.3
43.8
31.7
8.2
343 
1135 
1200 
537 
10.7 
35.3 
37.3 
16.7 
.000* 
sex Female 
male 
108
107
50.2
49.8
1665 
1616 
50.7 
49.3 
.884 
ADHD positive 
screen 
Yes (≥14) 
No (6-13) 
13
183
6.6
93.4
92 
3073 
2.9 
97.1 
.004 
ADHD 
diagnosis 
Previous diagnosis 
never 
5
208
2.3
97.7
67 
3208 
2.0 
98.0 
.764 
ADHD meds Taken 
Never taken 
1
212
0.5
99.5
49 
3226 
1.5 
98.5 
.220 
Distress (GHQ) Yes (≥3) 
No (0-2) 
42
172
19.6
80.4
427 
2854 
13.0 
87.0 
.006 
ASP screen Yes (≥3) 
No (0-2) 
2
203
1.0
99.0
9 
3177 
0.3 
99.7 
.091 
Anti-anxiety 
meds 
Taken last 12 mo 
No 
24
187
11.4
88.6
237 
3038 
7.2 
92.8 
0.27 
Anti-depressant 
meds 
Taken last 12 mo 
No 
15
200
7.0
93.0
208 
3066 
6.4 
93.6 
.717 
Anti-pain meds Taken last 12 mo 
No 
56
153
26.8
73.2
663 
2597 
20.3 
79.7 
.026 
Binge drinking 
5+ 
Yes (≥1past yr) 
No  
108
70
60.7
39.3
1344 
1284 
51.1 
48.9 
.014 
Cannabis use 
lifetime 
Yes (ever in lifetime) 
No (never) 
114
100
53.3
46.7
1329 
1938 
40.7 
59.3 
.000* 
Cocaine use 
lifetime 
Yes (ever in lifetime) 
No (never) 
25
190
11.6
88.4
217 
3060 
6.6 
93.4 
.005 
AUDIT Yes (≥8) 
No (0-7) 
28
173
13.9
86.1
422 
2785 
13.2 
86.8 
.754 
ASSIST Moderate/high (≥4) 
Low (0-3) 
25
190
11.6
88.4
137 
3137 
4.2 
95.8 
.000* 
Drinking 
driving 
Past yr 
No 
8
206
3.7
96.3
184 
3097 
5.6 
94.4 
.254 
Cannabis 
driving 
Past yr 
No 
7
208
3.3
96.7
60 
3198 
1.8 
98.2 
.144 
Racing Past yr 
No 
9
205
4.2
95.8
26 
3245 
0.8 
99.2 
.000* 
*Significant P value with Bonferroni adjustment for 18 comparisons = .0028 
Table 3 Sequential Logistic regression for self-reported collision involvement in past 12 
months 
 β S.E. Wald df Sig. Exp (β) 95% C.I. 
 Constant -2.794 .080 1219.574 1 .000 .061
Block 1  
    Age Group    18-24 18.990 3 .000 
                          25-44 .138 .255 .295 1 .587 1.148 .697-1.893
                          45-64 -.458 .270 2.883 1 .090 .633 .373-1.073
                         65+ -.963 .370 6.769 1 .009 .382 .185-.789
    Sex (Male) .060 .164 .131 1 .717 1.061 .769-1.465
    Driving km in a week .000 .000 5.949 1 .015 1.000 1.000-1.001
  Constant -2.717 .242 125.756 1 .000 .066
Model X2 =26.568, df=5, P<.000 
-2 Log likelihood=1241.489 
Hosmer and Lemeshow Test 
X2=3.201, df=8, P=.921 
 
Block 2  
     Age Group    18-24 18.708 3 .000 
                          25-44 .142 .255 .309 1 .578 1.152 .699-1.901
                          45-64 -.450 .270 2.802 1 .094 .636 .375-1.080
                          65+ -.953 .371 6.599 1 .010 .386 .186-.798
    Male .059 .164 .129 1 .720 1.06 .769-1.464
    Weekly Driving km  .000 .000 6.026 1 .014 1.000 1.000-1.001
    ADHD+ Status  .156 .423 .135 1 .713 1.169 .510-2.679
  Constant -2.727 .244 124.771 1 .000 .065
Model X2=26.699, df=6, P<.000 
-2 Log likelihood=1241.359 
Hosmer and Lemeshow Test 
X2=2.901, df=8, P=.940 
 
Block  3  
    Age Group    18-24 17.871 3 .000 
                          25-44 .127 .256 .247 1 .619 1.135 .688-1.874
                          45-64 -.455 .271 2.827 1 .093 .634 .373-1.078
                         65+ -.944 .371 6.460 1 .011 .389 .188-.806
    Male .051 .165 .94 1 .759 1.052 .761-1.455
    Weekly Driving km  .000 .000 6.331 1 .012 1.000 1.000-1.001
    ADHD+ Status  .021 .439 .002 1 .962 1.021 .432-2.415
   ASPD (+) 1.113 .832 1.790 1 .181 3.042 .596-15.522
   GHQ(3+) .175 .224 .610 1 .435 1.191 .768-1.849
Constant -2.747 .248 122.940 1 .000 .064
Model X2=28.796, df=8, P<.000 
-2 Log likelihood=1239.262 
Hosmer and Lemeshow Test 
X2=5.976, df=8, P=.650 
 
Block 4  
    Age Group    18-24 14.099 3 .003 
                          25-44 .185 .263 .496 1 .481 1.203 .719-2.013
                          45-64 -.369 .279 1.749 1 .186 .692 .400-1.195
                         65+ -.745 .380 3.838 1 .050 .475 .225-1.000
    Male .008 .167 .003 1 .959 1.009 .727-1.399
    Weekly Driving km  .000 .000 5.846 1 .016 1.000 1.000-1.001
    ADHD+ Status  -.126 .446 .080 1 .777 .882 .368-2.113
   ASPD (+) 1.024 .849 1.456 1 .228 2.784 .528-14.690
   GHQ(3+) .108 .227 .228 1 .633 1.114 .715-1.737
   ASSIST .567 .315 3.248 1 .071 1.763 .952-3.266
  Used Cannabis in Lifetime .339 .177 3.659 1 .056 1.404 .992-1.988
  Used Cocaine in Lifetime -.005 .294 .000 1 .987 .995 . 559-1.771
Constant -2.987 .265 126.622 1 .000 .050
Model X2=38.317, df=11, P<.000 
-2 Log likelihood=1229.741 
Hosmer and Lemeshow Test 
X2=3.296 df=8, P=.914 
 
 
  
 
  
